Estrogen Receptor Beta Pipeline Review, H2 2020 Report: Approx 20 Molecules – 14 Molecules are Developed by Companies and Remaining by the Universities/Institutes – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Estrogen Receptor Beta – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

‘Estrogen Receptor Beta – Pipeline Review, H2 2020’; Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 20 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription.

The report ‘Estrogen Receptor Beta – Pipeline Review, H2 2020’ outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 5, 3 and 5 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 2 and 2 molecules, respectively.

Scope

• The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
• The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics

Key Topics Covered:

Introduction

• Report Coverage

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Overview

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Therapeutics Development

• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Companies Involved in Therapeutics Development

• AstraZeneca Plc
• Atossa Therapeutics Inc
• Avivia BV
• Eagle Pharmaceuticals Inc
• Eli Lilly and Co
• Endece LLC
• EndoCeutics Inc
• Helixmith Co Ltd
• Huons Co Ltd
• Karo Pharma AB
• Kissei Pharmaceutical Co Ltd
• MEI Pharma Inc
• Oasmia Pharmaceutical AB

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Drug Profiles

(bazedoxifene acetate + cholecalciferol) – Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

• acolbifene + prasterone – Drug Profile
• AUS-131 – Drug Profile
• dehydrodiconiferyl alcohol – Drug Profile
• Drug to Agonize ER-Beta for Multiple Sclerosis – Drug Profile
• erteberel – Drug Profile
• estradiol – Drug Profile
• fosfestrol – Drug Profile
• fulvestrant – Drug Profile
• fulvestrant – Drug Profile
• fulvestrant – Drug Profile
• KB-3944 – Drug Profile
• KB-9520 – Drug Profile
• Libidua – Drug Profile
• Loseasonique – Drug Profile
• NDC-1308 – Drug Profile
• Small Molecule to Agonize ESR2 for Obesity and Depression – Drug Profile
• Small Molecule to Agonize ESR2 for Oncology – Drug Profile
• Small Molecules to Agonize ESR2 for Multiple Sclerosis – Drug Profile
• Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology – Drug Profile
• SR-16234 – Drug Profile

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Dormant Products

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Discontinued Products

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Product Development Milestones

• Featured News & Press Releases
• May 04, 2020: Eagle Pharmaceuticals advances novel and proprietary formulation of Fulvestrant product candidate EA-114; company to request additional meeting with U.S. Food and Drug Administration

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fsjdyd

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900